CINCINNATI, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (the “Company”) (TSXV: PHM), a healthcare services company with operations in the U.S., today announced its third quarter financial results and operational highlights.

Financial highlights from the third fiscal quarter ending June 30, 2018:

  • Revenue for the third quarter of $19.7 million, compared to $18.7 million in the second quarter, an increase of 5.3%
  • Adjusted EBITDA for the third quarter of $3.6 million, compared to $2.2 million in the second quarter, an increase of 60.3%
  • Adjusted EBITDA margins increased to 18.3% in the third quarter from 12.0% in the second quarter
  • Cash increased 10% to $4.4 million as compared to second quarter.          

Operational highlights from the third fiscal quarter ending June 30, 2018:

  • Through our use of technology and establishing our national fulfillment center, resupply deliveries increased from 8,444 in 2017 Q3 to 10,245 in the current quarter, an increase of approximately 30%
  • As a result of excellent patient care, achieved 6% organic growth in our patient base.
  • As a result of our investment in establishing our centralized billing platform, our bad debt expense has reduced substantially and is less than 10%

The interim financial statements of the Company for the three and nine months ended June 30, 2018 and 2017 and accompanying Management's Discussion & Analysis (MD&A) are available at

“I am very pleased with our third quarter financial results,” said CEO and Chairman Greg Crawford. “It has only been eight months since our current management team has been in place and in the short six months of reported results, we have begun to clearly demonstrate that we are capable of increasing revenues and margins while maintaining a relatively conservative balance sheet with a healthy cash position. We are starting to see the results of the implementation of our revised corporate strategy that incorporates technology, organic growth and strategic acquisitions which we believe will continue to improve our overall financial results on a go forward basis.”


The Company provides in-home monitoring and disease management services for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The initial service line includes in-home monitoring equipment, supplies and services to patients in the U.S. who take prescription blood thinners, such as Coumadin® (warfarin).

The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, including the Company’s revised corporate strategy improving overall financial results on a go forward basis, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the Company’s ability to maintain/slightly increase its collections ratios; the Company maintaining its gross margins and maintaining its revenue growth; and the Company maintaining its selling, general and administrative expenses. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: credit; market (including equity, commodity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; and the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Non-GAAP Measures

This press release refers to “Adjusted EBITDA” which is a non-GAAP and non-IFRS financial measure that does not have a standardized meaning prescribed by GAAP or IFRS. The Company’s presentation of this financial measure may not be comparable to similarly titled measures used by other companies. This financial measure is intended to provide additional information to investors concerning the Company’s performance. Adjusted EBITDA is defined as EBITDA excluding stock based compensation and gains/losses on financial derivatives. Adjusted EBITDA is a Non-IFRS measure the Company uses as an indicator of financial health, and excludes several items which may be useful in the consideration of the financial condition of the Company, including interest expense, taxes, depreciation, amortization, stock based compensation, good will impairment and gain/losses on financial derivatives. The following table shows our Non-IFRS measure (Adjusted EBITDA) reconciled to our net income for the indicated periods:

3 Months Ended  June 30, 2018 
Net Income $  (1,443)
Add back:  
Depreciation and amortization  4,195 
Interest expense (net of interest income)  396 
Provision (recovery) for income taxes  0 
EBITDA $  3,148 
Stock-based compensation  404 
Gain on disposal of business  0 
Gain on financial derivatives  49 
Adjusted EBITDA $  3,601  

Management uses these non-GAAP measures as key metrics in the evaluation of the Company’s performance and the consolidated financial results. The Company believes these non-GAAP measures are useful to investors in their assessment of the operating performance and the valuation of the Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors. However, non-GAAP financial measures are not prepared in accordance with GAAP, and the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information please visit our website at, or contact:

Hardik Mehta
Chief Financial Officer

Protech Home Medical Corp.